Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhuFlt3L/CDX-301 and Poly-ICLC + Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas
NCT01976585Phase 2Completed
- Start
- Jan 2014
- Primary completion
- Nov 2020
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Flt3 ligand and poly iclc in B cell lymphoma and cutaneous T-cell lymphoma (CTCL). Primary endpoint: Objective Response Rate at 12 weeks. Started Jan 2014; status: completed.
02
Drugs
Flt3 ligandpoly iclc
03
Conditions
B cell lymphomacutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01976585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01976585.